3 results
Approved WMOCompleted
The objective of this trial is to evaluate the activity and safety of Brostallicin used as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma.
Approved WMOCompleted
Primary Objective* To compare the effect of a 30-week course of mavacamten with placebo on clinical response comprising of exercise capacity and clinical symptoms in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)…
Approved WMORecruiting
Primary Objectives: • To assess the efficacy of a 48-week course of mavacamten compared to placebo on patient- reported health status (symptoms and physical limitations)• To assess the efficacy of a 48-week course of mavacamten compared to placebo…